Skip to main content

Table 3 Patients with AGel amyloidosis in the FIN-GAR phase II registry with specific symptomatic treatments

From: Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study

Symptomatic treatment and follow

Frequency (%)

n

Total

Moisturizing skin creams

85

110

129

Skin and soft tissue surgery

65

170

261

Artificial tears

46

121

261

Carpal tunnel syndrome surgery

26

68

261

Cataract surgery

24

62

261

Hearing aid or cochlear implant

9

23

261

Pacemaker

5

12

261

Kidney transplantation

2

5

261

Dialysis

1

3

261